Clinical trials: Cutaneous Melanoma, Stage IV
Melanoma (Skin)
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00006385
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- 32 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Unresectable Cutaneous Melanoma
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma.
- Trial name
- MORALE-MM (NCT07631325)
- Testing
- Axelopran, Nivolumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- John Kirkwood
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.
- Trial name
- NCT00002817
- Testing
- sargramostim, vaccinia-GM-CSF vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00022438
- Testing
- aldesleukin, incomplete Freund's adjuvant, recombinant tyrosinase-related protein-2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin Cancer)
Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
1. Primary Objective To evaluate the efficacy and safety of cadonilimab in combination with high-dose recombinant human interferon α1b injection as neoadjuvant therapy in patients with stage III/IV melanoma.
- Trial name
- NCT07586904
- Testing
- Cadonilimab and Recombinant Human Interferon α1b Combination Therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xijing Hospital
Melanoma (Skin)
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602576
- Testing
- sorafenib tosylate, temozolomide
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Abramson Cancer Center at Penn Medicine